Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
Published:
How to Bypass Step Therapy with Aetna for GLP-1s: The 2026 Exception Guide That Actually Works
By The RX Index Editorial Team · Last verified: May 23, 2026
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This page contains affiliate links to Ro and other providers. Compensation does not influence content.
If Aetna just denied your Wegovy or Zepbound and told you to try phentermine first — you don’t have to play that game.
Here’s how to bypass step therapy with Aetna in plain English: you file a legitimate exception request, formulary exception, prior-authorization resubmission, or appeal — depending on what your denial letter actually says. If your prescriber documents that the required step drug failed, caused side effects, is contraindicated, is expected to be ineffective, could cause harm, or that you’re already stable on the requested medication, Aetna must review the request under its own published exception process.
That’s the “bypass.” It’s not a loophole. It’s a process Aetna doesn’t advertise but is required to provide.
| Your Aetna denial says… | What it really means | First move | Deadline |
|---|---|---|---|
| “Step therapy required” | Try a cheaper drug first | Step therapy exception request | Plan-specific (see deadlines section) |
| “Drug not on formulary” | Plan doesn’t list this drug | Formulary exception request | Plan-specific |
| “Not medically necessary” | Aetna disagrees with your prescriber | Medical necessity appeal | Up to 15 business days |
| “Weight-loss drugs excluded” | Plan has a hard carve-out | Different game — see plan exclusion section | Plan-specific |
| “PA criteria not met” | Paperwork was incomplete | Resubmit with full documentation | Plan-specific |
First, figure out which kind of Aetna denial you actually have
Most failed Aetna appeals fight the wrong fight. Step therapy is one of four common denial types, and each one needs a completely different fix.
Your plan covers what your prescriber prescribed — but only after you’ve tried something else first. Common step drugs for GLP-1s on Aetna/CVS Caremark plans include phentermine, Contrave, Saxenda, Qsymia, and orlistat. For Zepbound specifically, the required step is often Wegovy itself.
Look for: “step therapy required,” “preferred alternative,” “fail first,” “you must try”
Fix: Step therapy exception request — see the exception section below.
Your plan doesn’t list this drug as a covered medication. In Aetna’s published Zepbound exception document, Wegovy is the primary formulary alternative, Mounjaro the secondary, and Zepbound the non-formulary agent.
Look for: “non-formulary,” “not on your plan’s drug list,” “not a covered medication”
Fix: Formulary exception request — your prescriber must document why the preferred alternative (usually Wegovy) won’t work for you.
Your plan covers the drug. Step therapy isn’t the issue. But Aetna decided your paperwork didn’t show you meet the PA criteria. Common gaps: BMI history, 6-month weight-management program documentation, comorbidity ICD-10 codes, or continuation evidence on renewal.
Look for: “PA criteria not met,” “additional documentation needed,” “does not meet medical necessity criteria”
Fix: Resubmit a complete PA. This is the easiest denial to overturn and the one people most often miss.
This is the toughest denial type because it’s not really a denial — it’s the absence of a benefit. Aetna’s Clinical Policy Bulletin 0039 states that many plans exclude weight-reduction medications entirely. It doesn’t matter how sick or how heavy you are — the plan doesn’t have a coverage bucket for these drugs.
Look for: “excluded benefit,” “weight loss drugs are not a covered benefit,” “your plan does not cover medications for weight loss”
Fix: Different game. Route through a different FDA indication, push your employer to add coverage at open enrollment, or go cash-pay.
If your letter is vague
Call the number on the back of your insurance card and ask this exact question: “Can you tell me whether this denial is for step therapy, prior authorization criteria, formulary exclusion, or a plan benefit exclusion?” Write down the answer. That answer determines your entire next move.
The 6 reasons Aetna may grant a step therapy exception
If your prescriber documents one of these six reasons, Aetna has to review the exception request under the rules that apply to your plan — but approval is not automatic. Your plan can still require medical-necessity documentation, diagnosis support, formulary rules, and benefit eligibility. These six grounds come from Aetna’s state-specific Step Therapy Protocol Exception Process documents verified for Maryland, Colorado, and Nevada.
Note: state step-therapy laws generally apply to state-regulated fully insured plans. Self-funded ERISA employer plans may follow different plan rules.
| # | The reason (in Aetna’s framework) | What your prescriber needs to show | How it applies to GLP-1s |
|---|---|---|---|
| 1 | The step drug is contraindicated | Documentation of the condition that makes the step drug unsafe | Phentermine is contraindicated in uncontrolled high blood pressure, recent heart attack, history of seizures, MAOI use, and hyperthyroidism. Documented contraindication supports skipping phentermine. |
| 2 | The step drug is expected to be ineffective for this patient | Clinical statement explaining why this case won’t respond | Your prescriber explains, in your specific clinical context, why the required step drug isn’t expected to produce a meaningful clinical response. |
| 3 | You already tried the step drug and it didn’t work, lost effect, or caused a bad reaction | Pharmacy fill records, prior prescriber notes, dates, dose, duration, outcome | The strongest version combines pharmacy fill history with prescriber notes documenting why the drug was stopped and what happened clinically. |
| 4 | The step drug is likely to cause harm to you | Provider documentation tying your medical history to expected harm | Borderline blood pressure plus phentermine’s stimulant effect is one common example, documented with specific clinical reasoning. |
| 5 | You’re stable on the drug you’re requesting (from prior coverage or appropriate prior use) | Prior pharmacy fills, prior plan EOB statements, or other documentation of stability | Aetna’s Maryland exception document explicitly says the requested medication may be covered when the insured is stable on it under current or prior coverage, subject to documentation and medical necessity requirements. |
| 6 | The step drug isn’t in your best clinical interest (available in some state statutes) | Provider rationale citing guidelines or patient-specific factors | This broader catch-all is specifically protected by several state step-therapy reform laws. |
Which ground actually applies to you?
- →Have you taken the required step drug under your current plan or a previous source of coverage, and can you document the date, dose, duration, and outcome? Ground 3.
- →Do you have uncontrolled high blood pressure, a seizure history, an eating disorder diagnosis, or any condition listed as a contraindication on the step drug’s label? Ground 1 or 4.
- →Does your prescriber believe, in your specific clinical context, that the required step drug won’t produce a meaningful response? Ground 2.
- →Have you been getting Wegovy or Zepbound from manufacturer cash-pay, samples, or a different insurance? Ground 5.
Don’t want to play paperwork project manager?
Ro Body (sponsored affiliate link, opens in a new tab)’s free GLP-1 Insurance Coverage Checker contacts your insurer for eligibility and sends a personalized coverage report. If you join Ro Body, the insurance concierge submits the PA, handles exception requests, and resubmits if denied. $39 first month, then as low as $74/month with annual prepay ($149/month monthly). Ro cannot coordinate GLP-1 coverage for government insurance plans.
Check your Aetna GLP-1 coverage with Ro — free report → (sponsored affiliate link, opens in a new tab)How to bypass step therapy with Aetna: file the exception request step by step
Aetna step therapy exception requests are filed by your prescriber through CVS Caremark — either via the Availity provider portal, by fax using Aetna’s prior authorization form, through CoverMyMeds, or by calling the Aetna Pharmacy Precertification Unit. Verify the current submission route through your plan documents.
Pull your denial letter
The denial letter tells you exactly what to fight. The pharmacy screen at CVS that says “PA required” doesn’t.
Pick your ground
From the six grounds above, pick the one (or two) that fit your situation best. Print the table. You’ll bring it to your prescriber.
Gather the evidence
Pharmacy fill history for any prior weight-loss drug, ICD-10 diagnosis codes (E66.01, E66.811, E66.812, E66.813; plus comorbidity codes I10, E11.9, G47.33, E78.5), six-month weight-management documentation (visit notes, nutritionist records, dietary logs, Noom records, gym records, WW records), contraindication documentation if using Ground 1 or 4, prior outcome notes if using Ground 3 or 5.
Talk to your prescriber
Bring everything from Step 3 to your appointment or message through the patient portal. Ask specifically: "Will you submit a step therapy exception request to Aetna citing [the ground number] from their published exception criteria?" Most prescribers don’t push back when you bring documentation.
Your prescriber files it
Through Availity, CoverMyMeds, the Aetna Pharmacy Precertification Unit phone line, or by fax. They’ll use the Aetna prescription drug prior authorization form with the exception rationale spelled out.
Mark your calendar
The deadline depends on which kind of request and which rules apply to your plan. See the deadlines section below.
Watch for the answer
Approved: your pharmacy will be notified. Denied: you’ll get a letter — move to the appeals section. No response in the applicable window: in some states, the request is deemed automatically granted.
Common mistakes that kill exception requests
- Submitting the exception without pharmacy fill records. A note that says “patient tried phentermine” is weaker than a printout showing dates, doses, and pharmacy.
- No comorbidity codes. “Patient has obesity” is weaker than “E66.812, I10, E78.5.”
- Submitting a step therapy exception when the real problem was incomplete PA paperwork. Different form, different fix.
- Citing emotional reasons instead of clinical ones. “I don’t want to take phentermine because of anxiety about side effects” doesn’t help. “Phentermine is contraindicated due to documented uncontrolled hypertension (I10) per drug label” does.
- Letting your prescriber’s office “do the appeal” without ever checking what they actually wrote. Some staff just resubmit the same denied PA. That’s not an appeal.
How long Aetna has to respond — and the deemed-granted leverage some states give you
Mark your calendar, but use the deadline that applies to your plan type. Some Medicare Part D and state-regulated step-therapy exception requests use 72-hour standard / 24-hour urgent windows after the prescriber’s supporting documentation is received. Aetna’s pharmacy FAQ says a coverage exception appeal can take up to 15 business days, with a second-level appeal taking another 15 business days. Federal external review must be completed no later than 45 days (72 hours for expedited).
Aetna Medicare Advantage Part D
Federal CMS rules apply: 72-hour standard, 24-hour expedited.
Aetna Better Health Medicaid
Use your state Aetna Better Health plan documents and Medicaid appeal rules. Coverage, criteria, and timelines are state-specific.
State-regulated commercial plan
Individual marketplace, small-group, and some fully-insured employer plans. Your state’s step therapy law applies on top of Aetna’s policy. This is where you get the “deemed granted” leverage.
Self-funded employer plan (ERISA)
Most large employers. State step therapy reform laws generally don’t apply. You still have Aetna’s own exception process and federal external review rights, but no state deemed-granted rule.
How to tell which one you have: Call your insurer and ask: “Is my plan fully insured or self-funded?” Or look in your Summary Plan Description. If it says “self-funded” or names an employer as the plan sponsor, it’s ERISA.
Verified state step-therapy override examples
Only publishing rows directly verified against current statute. About 30 states have some form of step therapy reform law.
| State | Standard response | Urgent response | Deemed granted if late? | Source |
|---|---|---|---|---|
| New York | 72 hours after supporting rationale/documentation is received | 24 hours | Yes | NY Public Health Law § 4903 / NY DFS Step Therapy FAQ |
| Nebraska | 5 days after receipt of documentation | 72 hours | Yes (statutory deemed-granted) | Nebraska Rev. Stat. § 44-7,115 |
What “deemed granted” actually means
In states with this provision (Nebraska is the clearest statutory example), if Aetna fails to respond to your step therapy override request within the legal window, the exception is automatically considered approved by operation of law. You may need to escalate to the state insurance department to enforce it, but the law is on your side. This is genuinely powerful leverage that most patients never use.
Tracking deadlines while managing a denial is a real second job
See if Ro can run your Aetna paperwork for you → (sponsored affiliate link, opens in a new tab)Not for Medicaid/government-funded plan members. (sponsored)
What if Aetna denies your step therapy exception?
A denied exception isn’t the end. You have at least three escalation paths: a Level 1 internal appeal, a peer-to-peer review where your prescriber speaks directly to an Aetna medical director, and an external review by an independent third party.
What the data says about GLP-1 appeal success
Industry data from Honest Care’s GLP-1 Patient Access Report (Q3/Q4 2025) — based on analysis of over 1,000 U.S. GLP-1 denial cases — shows roughly 65% of properly documented GLP-1 denials get overturned on first appeal. The most cited reasons appeals fail: incomplete documentation, missing prior medication history, and submitting the wrong type of appeal for the denial type. (This is the source’s number, not ours.)
File within 180 days of the denial letter. Aetna assigns it to a reviewer who didn’t make the original decision. Include: a member appeal letter, a new medical necessity letter from your prescriber citing exact Aetna Clinical Policy Bulletin language, all original documentation plus anything new, pharmacy fill records, comorbidity codes, and weight-management program proof. Aetna response: up to 15 business days; expedited if delay would jeopardize your health.
The underused move. Your prescriber requests a phone call directly with an Aetna medical director to discuss the case. The medical director can approve right there on the phone if your prescriber makes a strong clinical case. Usually scheduled within 1–2 business days. Works especially well when your prescriber can cite specific clinical literature, you have comorbidities the original reviewer didn’t fully weigh, or your case has nuance that doesn’t fit the PA checklist.
After internal appeals are exhausted, request independent external review. Aetna’s external review program applies when the denial involves more than $500 in services and is based on medical necessity or experimental/investigational determinations. Federal rules (45 CFR § 147.136) confirm the external reviewer’s decision is binding on the insurer. External review is free to you. Standard: no later than 45 days. Expedited: no later than 72 hours.
For state-regulated plans, file a complaint with your state’s department of insurance. This often gets faster Aetna responses because Aetna prefers to settle complaints than respond to regulators.
What documents your prescriber should attach to an Aetna step therapy exception
This is the master checklist. Print it. Bring it to your appointment. Hand it to your prescriber’s office.
Patient and plan information
- ☐Member ID and plan name (from your insurance card)
- ☐Prescribing prescriber NPI and contact info
- ☐Denial letter (full copy, both sides)
Diagnosis evidence
- ☐BMI documentation (current plus historical trajectory)
- ☐ICD-10 codes for obesity (E66.01, E66.811, E66.812, E66.813)
- ☐ICD-10 codes for any comorbidity (I10, E11.9, G47.33, E78.5, etc.)
Prior medication history (Grounds 3 and 5)
- ☐Drug name, dose, start/stop dates, duration
- ☐Outcome (inadequate response, adverse event, intolerance)
- ☐Pharmacy fill history printout
- ☐Prescriber notes documenting why the drug was stopped
Contraindication / harm evidence (Grounds 1 and 4)
- ☐Specific medical condition that makes the step drug unsafe
- ☐Reference to drug label or clinical guidelines
- ☐Prescriber attestation
Clinical rationale (Grounds 2 and 6)
- ☐Patient-specific reasoning why the step drug isn’t expected to work
- ☐Severity of obesity / comorbidity burden
- ☐Guidelines or literature support
Comprehensive weight-management program documentation
- ☐Program name (if applicable)
- ☐Dates of participation (at least 6 months for Wegovy PA)
- ☐Diet/activity counseling notes
- ☐Follow-up records
Stability evidence (Ground 5)
- ☐Prior pharmacy fills or EOBs showing prior coverage of the requested drug
- ☐Clinical notes documenting stability
Wegovy through Aetna: what’s actually happening in 2026
Wegovy is the primary formulary alternative in the referenced Aetna/CVS Caremark Zepbound exception design, and many Aetna/CVS Caremark plans may evaluate Wegovy with prior authorization. Some employer/self-funded plans exclude weight-loss medications entirely.
Common documentation gaps that cause Wegovy denials
- •Missing 6-month comprehensive weight-management documentation. Aetna’s Wegovy policy specifically requests participation in a comprehensive weight-management program — diet, exercise, behavior counseling — for at least six months.
- •No documented BMI history or trajectory.
- •No comorbidity ICD-10 codes. “Patient has high cholesterol” is weaker than “E78.5.”
- •Continuation denial. For adult continuation, Aetna’s current Wegovy criteria require documentation that the patient completed at least 3 months at a stable maintenance dose and either lost at least 5% of baseline body weight or maintained the initial 5% loss. Initial therapy approval: 7 months. Continuation approval: 12 months.
The cardiovascular indication pathway
In March 2024, the FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and overweight/obesity. If you have documented heart disease (post-heart attack, stroke history, established coronary artery disease, peripheral artery disease), some plans may evaluate Wegovy under the cardiovascular indication even when weight-loss coverage is excluded. Coverage is still plan-specific and the PA has to be filed under the cardiovascular indication, not the obesity indication.
Zepbound through Aetna: the formulary exception problem
In the referenced Aetna/CVS Caremark Zepbound exception design, Wegovy is listed as the primary formulary alternative, Mounjaro as the secondary alternative, and Zepbound as the non-formulary agent. Getting Zepbound covered means filing a formulary exception — a different request from a step therapy exception. The documented question is whether the patient can be treated with Wegovy.
Your strongest documentation for a Zepbound formulary exception
A surprising number of Zepbound denials get overturned because the patient already had a brief Wegovy trial on a previous plan and didn’t realize that history counted as documentation.
The obstructive sleep apnea (OSA) indication
In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Some plans may evaluate Zepbound under its FDA-approved OSA indication if the plan covers that indication and the sleep study and obesity documentation support it. It’s not automatic and does not override every plan exclusion. If you have documented moderate-to-severe OSA (AHI 15+ on a sleep study) and obesity, ask your prescriber about filing under the OSA indication.
Should you just switch to Wegovy?
The unglamorous truth: for many people, switching to Wegovy is faster than fighting for Zepbound. They’re different molecules — semaglutide vs. tirzepatide — that work differently. If your real goal is being on an FDA-approved GLP-1 quickly with insurance paying, Wegovy is the path of least resistance under the current Aetna/CVS Caremark design. If your goal is specifically tirzepatide for clinical reasons, fight the formulary exception with strong documentation of why Wegovy won’t work.
What about Ozempic, Mounjaro, and Foundayo through Aetna?
Ozempic (semaglutide for type 2 diabetes)
Coverage typically depends on type 2 diabetes-related criteria. Not covered for weight loss alone. PA criteria focus on diabetes diagnosis (A1C documentation) and prior diabetes drug trials. If you want semaglutide for weight loss, Wegovy is the path.
Mounjaro (tirzepatide for type 2 diabetes)
Same coverage pattern as Ozempic — plan- and diagnosis-specific. If you have type 2 diabetes and want tirzepatide, Mounjaro is the path. If you want tirzepatide for weight loss only, Zepbound is the (harder) path. We cover Mounjaro PA specifics in our insurance coverage guides.
Foundayo (orforglipron — FDA-approved April 1, 2026)
Foundayo is the first non-peptide oral GLP-1 pill, approved for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. We have not separately verified Aetna formulary placement for Foundayo at the time of this article. Check your specific Aetna formulary before assuming coverage. If not covered, the cash-pay starting price is $149/month through Ro.
If Aetna says you have to try metformin first — read this before you do anything
Some Aetna denial letters list metformin as a required step. Metformin is a diabetes drug. It’s not an obesity drug. If you’re being told to try metformin before a GLP-1, one of two things is happening:
You actually have a type 2 diabetes diagnosis (or pre-diabetes documented), and Aetna is applying the diabetes coverage pathway. A metformin trial may be a legitimate step. Your prescriber can document if there’s a clinical reason to skip metformin (lab abnormalities, intolerance, contraindication).
The denial letter is from a different coverage pathway than the one you actually qualify for. The fix is to make sure your prescriber submitted under the right indication (obesity for Wegovy, type 2 diabetes for Ozempic), not to add a metformin trial that doesn’t really apply.
What you should not do
Ask your prescriber to write a diagnosis you don’t have so the coverage pathway changes. Diagnosis shopping is insurance fraud, it can void your coverage, and it can put your prescriber’s license at risk. The legitimate moves are filing the right exception request for the indication you actually qualify for, switching to a drug whose indication you actually meet, or going cash-pay if neither works.
What if your Aetna plan excludes weight-loss drugs entirely?
A plan exclusion is fundamentally different from step therapy. The plan doesn’t have a coverage bucket for these drugs at all, so an exception request usually can’t fix it. Your three real options: route the prescription through a different FDA-approved indication, push your employer to add coverage, or move to a cash-pay path.
Check your Summary Plan Description (available through your Aetna member portal under “Plan Documents”). Search for “weight,” “obesity,” “anti-obesity,” or “weight management.” A real exclusion will be spelled out explicitly: “Weight loss medications are not a covered benefit.” If you can’t find that language, call Aetna and ask.
If you have documented heart disease, ask about Wegovy’s cardiovascular indication. If you have documented OSA on a sleep study, ask about Zepbound’s OSA indication. Both bypass weight-loss carve-outs because the drug is prescribed for the FDA-approved cardiovascular or sleep apnea indication — not weight loss.
If your plan is employer-sponsored (especially self-funded ERISA), the exclusion is a benefit design choice your employer made. Many large employers are reconsidering GLP-1 coverage as Medicare expands and as manufacturer pricing comes down. Open enrollment is your window. Email HR. Cite KFF data showing roughly 19% of large employers now cover GLP-1s for weight loss.
If none of the above works, the cash-pay options are now genuinely affordable compared to a year ago. See the cash-pay backup section below.
Not sure whether to push your employer, switch indications, or go cash-pay?
Take the free 60-second GLP-1 matching quiz →Who should actually handle your Aetna appeal — your PCP, an obesity specialist, Ro, or Sesame Care?
The best person to file your Aetna exception is the one who can assemble the strongest documentation packet and follow up on deadlines.
| Path | Best when | What they do | Real limitation |
|---|---|---|---|
| Your PCP | You have a long relationship and your records are already there | Files PA, may file basic appeals, knows your full history | Most PCPs don’t have dedicated appeal specialists. Some won’t file beyond Level 1. |
| Obesity medicine specialist | Complex medical case, multiple comorbidities, prior failed treatments | Stronger clinical letters, deeper familiarity with PA criteria | Wait times for new patients can run 4–12 weeks. May not be in-network. |
| Ro Body | Paperwork and PA are the actual blocker, you want FDA-approved branded GLP-1s, you have commercial insurance | Free Insurance Coverage Checker contacts insurer for eligibility; insurance concierge submits PA, handles exceptions, resubmits if denied | Membership is cash-pay. $39 first month / as low as $74/month annual / $149/month monthly. Ro cannot coordinate GLP-1 coverage for government insurance plans. |
| Sesame Care | You want provider choice, video visits, brand-name GLP-1 options, and provider-level insurance support | Success by Sesame subscription includes telehealth visits, messaging, and ongoing clinical care from a provider of your choice | Less appropriate if you specifically want a dedicated insurance concierge model. Subscription starts at $59/month with annual plan. |
| DIY member appeal | You’re well-documented and detail-oriented | You assemble records and bring them to your prescriber; you track deadlines | The clinical letter still has to come from your prescriber. |
Ro Body: where it actually wins
Ro is built around this exact problem. Their free GLP-1 Insurance Coverage Checker asks for insurance-card information, contacts your insurer to collect eligibility information, and sends a personalized report showing coverage details and whether prior authorization may be required. Ro says the checker does not submit a treatment request or write prescriptions. Ro says new accounts receive a $50 credit when they receive their free coverage results.
Ro Body pricing (verify current at ro.co):
- • $39 for the first month
- • As low as $74/month with annual plan paid upfront
- • $149/month if you pay monthly
- • Ro cannot coordinate GLP-1 coverage for government insurance plans. If you have Medicaid, you cannot join Ro Body through Ro.
Sesame Care: provider choice + clinical support
Success by Sesame subscription includes telehealth video visits, messaging, and ongoing clinical care from a provider of your choice, starting at $59/month with annual plan. Less appropriate if you specifically want a dedicated insurance concierge model.
See GLP-1 options on Sesame Care → (sponsored affiliate link, opens in a new tab)If the appeals process runs out: your FDA-approved cash-pay backup plan
If your Aetna step therapy exception, formulary exception, internal appeal, and external review are all denied — or if your plan has a hard exclusion — your remaining FDA-approved paths are manufacturer cash-pay and cash-pay telehealth.
| Medication / dose | Channel | Cash-pay price | Notes |
|---|---|---|---|
| Wegovy pill 1.5 mg | NovoCare | $149/month | NovoCare current price guide |
| Wegovy pill 4 mg | NovoCare | $149/month through Aug 31, 2026; $199/month thereafter | NovoCare price guide |
| Wegovy pen 0.25 / 0.5 mg (intro) | NovoCare | $199/month for two monthly fills through June 30, 2026 | NovoCare price guide |
| Wegovy pen 0.25–2.4 mg | NovoCare | $349/month (standard cash-pay) | After intro window |
| Wegovy HD 7.2 mg | NovoCare | $399/month | NovoCare price guide |
| Zepbound vial 2.5 mg | LillyDirect Self Pay Journey | $299/month | When program conditions are met |
| Zepbound vial 5 mg | LillyDirect Self Pay Journey | $399/month | Self Pay Journey program |
| Zepbound vial (other approved doses) | LillyDirect Self Pay Journey | $449/month | Program-specific |
| Zepbound | TrumpRx | from $299/month | Verify current dose-specific pricing |
| Foundayo (orforglipron) | Ro and other channels | from $149/month | FDA approved April 1, 2026 |
Verify dose, channel, and eligibility before acting — manufacturer pricing programs change frequently.
A note on compounded GLP-1s
Compounded GLP-1 medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality before being marketed. They are not equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA has explicitly published concerns about dosing errors, semaglutide salt forms, and adverse events involving compounded GLP-1 products. We don’t recommend compounded as a first-line cash-pay path on this page. The cleanest backup is the same FDA-approved medication at manufacturer cash-pay pricing.
What this page will NOT help you do
- ×No diagnosis shopping. We won’t show you how to “get diagnosed with diabetes” to switch coverage pathways.
- ×No misrepresenting medication trials. Saying you took a drug you didn’t take is insurance fraud.
- ×No hiding side effects or history from your prescriber.
- ×No “say you have sleep apnea” advice without a sleep study.
- ×No buying GLP-1s from unapproved overseas sellers or unlicensed sources.
The legitimate exception process on this page is the right path for people who actually meet a documented exception ground.
What we actually verified
Last verified: May 23, 2026 · Next scheduled review: August 2026
| Element | Source | Verified |
|---|---|---|
| Aetna step therapy exception criteria (six grounds) | Aetna Maryland / Colorado / Nevada Step Therapy Protocol Exception Process PDFs | ✅ May 23, 2026 |
| Aetna Wegovy PA criteria including continuation (3 months stable + 5% loss; 7-month initial / 12-month continuation) | Aetna Pharmacy Clinical Policy Bulletin for Wegovy | ✅ May 23, 2026 |
| Aetna Zepbound formulary exception (Wegovy primary, Mounjaro secondary, Zepbound non-formulary) | Aetna Zepbound Exception bulletin | ✅ May 23, 2026 |
| Aetna plan exclusion language | Aetna Clinical Policy Bulletin 0039 — Obesity | ✅ May 23, 2026 |
| Aetna external review eligibility ($500 threshold, medical necessity/experimental) | Aetna External Review Program page | ✅ May 23, 2026 |
| Federal external review rules and timing | 45 CFR § 147.136 (eCFR), HealthCare.gov | ✅ May 23, 2026 |
| Aetna pharmacy FAQ appeal timing (up to 15 business days; second-level up to 15 BD if allowed) | Aetna pharmacy FAQ | ✅ May 23, 2026 |
| New York step therapy timing (72h/24h, deemed granted) | NY PHL § 4903; NY DFS Step Therapy FAQ | ✅ May 23, 2026 |
| Nebraska step therapy timing (5 days standard / 72h urgent, deemed granted) | Nebraska Rev. Stat. § 44-7,115 | ✅ May 23, 2026 |
| CMS Medicare GLP-1 Bridge ($50/month, July 1, 2026 – Dec 31, 2027) | CMS press release | ✅ May 23, 2026 |
| Foundayo FDA approval (April 1, 2026) | FDA press release | ✅ Confirmed |
| Wegovy CV indication (March 2024) and Zepbound OSA indication (December 2024) | FDA approvals | ✅ Confirmed |
| Ro insurance concierge process, free checker scope, government insurance limitation | ro.co/weight-loss/insurance/, ro.co/weight-loss/glp1-insurance-checker/ | ✅ May 23, 2026 |
| NovoCare cash-pay pricing by dose | NovoCare Wegovy Price Guide PDF | ✅ May 23, 2026 |
| LillyDirect Self Pay Journey Zepbound pricing | LillyDirect | ✅ May 23, 2026 |
| FDA position on compounded GLP-1s | FDA: “FDA’s concerns with unapproved GLP-1 drugs used for weight loss” | ✅ May 23, 2026 |
Sourced but not independently verified: Industry appeal-success rate (~65%) is from Honest Care’s GLP-1 Patient Access Report (Q3/Q4 2025). We cite the source — we didn’t run our own analysis.
Not verified by us: Aetna formulary placement for Foundayo. Reader must check their plan formulary.
Frequently asked questions
Can Aetna step therapy actually be bypassed?
Yes — through a documented exception request when your situation matches one of the six grounds Aetna’s exception process recognizes. The strongest grounds are prior failed trial, contraindication, expected ineffectiveness, expected harm, and current stability on the requested drug. Approval is not automatic — your plan can still require medical-necessity documentation and benefit eligibility.
What’s the difference between step therapy and prior authorization?
Prior authorization (PA) is your insurer requiring approval before they pay for a drug. Step therapy is your insurer requiring you to try a different drug first. PA can apply without step therapy. Step therapy almost always includes a PA. The forms and the exception process are different.
How long does an Aetna step therapy exception take?
It depends on which kind of request and which rules apply to your plan. Some Medicare Part D and state-regulated step-therapy exception requests use 72-hour standard / 24-hour urgent windows after the prescriber’s supporting documentation is received. Aetna’s pharmacy FAQ says a coverage exception appeal can take up to 15 business days, with second-level appeals taking another 15 business days if your plan allows them.
Does Aetna cover Wegovy in 2026?
Coverage is plan-specific. On many Aetna/CVS Caremark plans, Wegovy may be evaluated with prior authorization. The referenced Aetna Zepbound exception design lists Wegovy as the primary formulary alternative. Some employer/self-funded plans still exclude all weight-loss drugs regardless of insurer.
Does Aetna cover Zepbound in 2026?
Coverage is plan-specific. In the referenced Aetna/CVS Caremark exception design, Zepbound is treated as non-formulary with Wegovy listed as the primary alternative. Many Aetna plans require either a formulary exception (documenting why Wegovy won’t work) or use of Zepbound’s FDA-approved OSA indication.
Can I file an Aetna appeal myself or does it have to be my prescriber?
You can file your member portion of the appeal yourself (the cover letter, the request to reconsider). The clinical documentation has to come from your prescriber because Aetna’s review requires diagnosis, lab values, contraindications, and medical records.
What if my prescriber won’t appeal the denial?
Two options: bring documentation to your prescriber showing exactly what Aetna needs (this often gets reluctant offices on board), or work with a telehealth provider like Ro that runs PA and appeals as part of their service for commercial plans. If a prescriber still won’t help you on a medically reasonable case, that’s a sign to find one who will.
Does state law force Aetna to approve my exception?
Only for state-regulated plans (mostly individual marketplace, small group, and some fully-insured employer plans). About 30 states now have step therapy reform laws. Self-funded employer plans (most large employers) are ERISA-regulated and generally exempt from state law — but you still have Aetna’s own exception process and federal external review rights.
What does “deemed granted” mean?
In some states (Nebraska is the clearest statutory example), if the insurer fails to respond to a step therapy override request within the legal window, the exception is automatically approved by operation of law. You may need to push the state insurance department to enforce it. Always verify the current state statute before relying on this leverage.
Can compounded semaglutide replace Wegovy?
We won’t say they’re the same drug because they’re not. Compounded GLP-1s aren’t FDA-approved and aren’t reviewed by the FDA for safety, effectiveness, or quality before being marketed. If you’re choosing between compounded and an FDA-approved branded option you can afford cash-pay, the FDA-approved option is the cleaner path.
How much does it cost to file an Aetna exception?
Nothing. Filing is free. If you use Ro Body to handle the paperwork, you pay Ro’s $39 first month and then as low as $74/month with annual prepay (or $149/month with monthly billing) — that pays for the team and the program, not the filing.
What if I’m on Medicare Advantage or Medicaid through Aetna?
Different rules apply. Aetna Medicare Advantage Part D plans follow federal CMS exception rules: 72h standard, 24h expedited. Beginning July 1, 2026, eligible Medicare beneficiaries with Part D coverage may be able to access certain GLP-1 medications for $50/month through the CMS Medicare GLP-1 Bridge, running through December 31, 2027. Aetna Better Health Medicaid plans follow state-specific Medicaid rules — coverage, criteria, and timelines vary by state. Ro cannot coordinate GLP-1 coverage for government insurance plans.
Your next step in the next 24 hours
The single highest-leverage action right now: identify which of the four denial types is on your letter and which of the six exception grounds applies to your situation.
Run Ro’s free Aetna coverage check
It asks for your insurance information, contacts Aetna for eligibility, and sends a personalized report. If you join Ro Body, their concierge handles the PA, the step therapy exception, and appeals for commercial plans.
Not for Medicaid/government-funded plan members.
Take this article to your prescriber
Print the six grounds in the exception section and the documentation checklist, bring your pharmacy history and any prior diagnosis records, and ask them specifically to submit a step therapy exception citing the ground that fits your case.
Still not sure whether to fight Aetna or switch to cash-pay?
Our 60-second matching quiz figures out which path actually fits your situation, your state, and your medication preference.
Related guides on The RX Index
Last verified: May 23, 2026 · Last updated: May 23, 2026 · Next scheduled review: August 2026
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We do not provide medical or legal advice. Always consult your prescriber and review your specific plan documents.
Affiliate disclosure: This page contains affiliate links to Ro and other GLP-1 telehealth providers. If you sign up through these links, we may earn a commission at no additional cost to you. Compensation does not influence the content of this page. Ro states that its members were paid for testimonials. Ro cannot coordinate GLP-1 coverage for government insurance plans. Compounded GLP-1 medications referenced on this page are not FDA-approved and are not equivalent to FDA-approved branded medications.